IRA Implications Will Factor Significantly In Deal Strategy In 2023

PwC Expects More Deals, But Affected By IRA

A pair of new PwC reports project a more robust M&A environment in 2023, but questions about the impact of the Inflation Reduction Act are already affecting biopharma business development strategies.

2023 business development start
Uncertainty about drug pricing implications of IRA could stall deal-making, PwC says • Source: Shutterstock

While consultancy PwC generally is bullish about increased deal-making and M&A activity by the biopharmaceutical sector in 2023, in a recent report it notes that the drug-pricing implications of last year’s Inflation Reduction Act will be a critical factor in how companies set up their business development strategies.

In its Next in Pharma: Thriving in 2023 report issued on 5 January, PwC said industry firms are making initial...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business

In Brief: Concentra Snaps Up Struggling IGM Biosciences In Latest Biotech Deal

 

Concentra Biosciences is acquiring struggling IGM Biosciences for $1.25 per share plus a contingent value right, with the deal expected to close in August 2025.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: AbbVie’s big autoimmune CAR-T play; In Vivo CAR-T interest grows; China deal perspectives from BIO; global pharma interest in Korea undeterred; and a look at the biggest drug sales disappointments.

Second Quarter M&A Activity Looks Like More Of The Same, Mostly

 
• By 

The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.